尿Cyfra21—1和B超联合检查在膀胱移行细胞癌术后监测中的意义  

Role of urine cyfra21 - 1 detecting combined with uhrasonography in the postoperative surveillance of bladder transitional cell carcinoma patients

作　　者：罗广承[1] 白培明[1] 刘莉莉[1] 陈卉品[1] 苏汉忠[1] 沈瑞雄[1] 

机构地区：[1]厦门大学附属中山医院泌尿外科,福建361004

出　　处：《国际泌尿系统杂志》2008年第6期727-729,共3页International Journal of Urology and Nephrology

摘　　要：目的评价尿Cyfra21-1和B超联合检查在膀胱移行细胞癌术后监测中的作用，探讨替代膀胱镜检查的可行性。方法对67例膀胱移行细胞癌患者术后定期行尿Cyfra21—1、B超和膀胱镜检查。电化学发光免疫分析（ECLIA）技术测定尿Cyfra21—1。以膀胱镜活检病理结果为标准，评估尿Cyfra21—1和B超联合检查对膀胱移行细胞癌术后监测的意义。结果67例膀胱移行细胞癌患者术后34个月内膀胱镜活检发现21例复发；尿Cyfra21—1检测阳性23例；B超检测阳性19例；尿Cyfra21—1和B超联合检查阳性26例，漏诊1例，漏诊率为4．76％。尿Cyfra21—1和B超联合检查与膀胱镜检查比较，经X^2检验无显著性差异（P〉0．05）。结论尿Cyfra21—1和B超联合检查可以部分替代膀胱移行细胞癌患者术后的膀胱镜检查。Objectives To investigate the role of routine follow - up urine cyfra21 - 1 detecting combined with uhrasonography in detection of recurrence in postoperative bladder transitional cell carcinoma patients. Methods Sixty seven patients under surveillance after reserved bladder operations were recruited from February 2004 to December 2006. Standard ECLIA was used to determine the concentration of urine cyfra21 - 1. Uhrasonography and cystoscopy were all performed several days thereafter. Cystoscopic biopsy findings were the golden standard for the detection of recurrence of bladder cancer. Results Twenty one patients were detected recurrent tumors by cystoscopic biopsy（31.3% ）. While 23 patients were positive by urine cyfra21 - 1 detecting, and 19 cases positive by ultrasonography. Combining urine cyfra21 - 1 measuring with ultrasonography, the positive cases rose to 26（38.8% ）, and only one case （4.76%） was omitted. Conclusions Routine follow - up cystoscopy may be partially replaced by urine cyfra21 - 1 detecting combined with ultrasonography to monitor the recurrence of bladder transitional cell carcinoma.

关 键 词：癌 移行性细胞 膀胱肿瘤 

分 类 号：R737.14[医药卫生—肿瘤]